-NSI-189 Showed Durable Functional Recovery in a
Rodent Model of Ischemic Stroke-
-NSI-189 Promoted Synaptic Remodeling After Stroke-
GERMANTOWN, Md., March 1 (Bernama-GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-189 in Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic plasticity in stroke-induced animals during the 12-week treatment period, which was maintained up to 24 weeks post-stroke.
No comments:
Post a Comment